May 19, 2020
Amplyx Pharmaceuticals Advances Development of Novel Antifungal, Fosmanogepix
Feb 13, 2020
SCYNEXIS Completes Patient Enrollment Ahead of Schedule in the Second Pivotal Phase 3 Study (VANISH-306) of Oral Ibrexafungerp for the Treatment of Vulvovaginal Candidiasis (Vaginal Yeast Infection)
Jan 08, 2020
U.S. FDA Approves Supplemental New Drug Application (sNDA) for Expanded Indication of MYCAMINE® (micafungin for injection) for the Treatment of Invasive Candidiasis in Pediatric Patients Less Than 4 Months of Age
Jan 08, 2020
SCYNEXIS Announces Positive Results from the Second Interim Analysis of Ongoing Phase 3 FURI Study, Demonstrating Oral Ibrexafungerp's Ability to Treat Severe Fungal Infections in the Hospital Setting
Dec 09, 2019
Stadius Biopharma to Present Data on Fully Human Antibodies for the Treatment of Candida Infections
Dec 09, 2019
Autoimmune Technologies Announces New Subsidiary to Develop Novel Antibody and Allogeneic Somatic Stem Cell Therapeutics For the Treatment of Invasive Candidiasis and Other Infectious Disease
Nov 14, 2019
SCYNEXIS Commends the CDC for the Recognition of Candida auris as a New "Urgent Threat" in its Updated Report on Antibiotic Resistance Threats in the United States
Nov 12, 2019
SCYNEXIS Reports Third Quarter 2019 Financial Results and Provides Company Update
Oct 24, 2019
SCYNEXIS Expands FURI Protocol to a Broader Range of Refractory Serious Fungal Infections, Building on Ibrexafungerp's Positive Data and Favorable Toxicology Profile Observed to Date
Oct 02, 2019
SCYNEXIS to Present Data at IDWeek 2019 and the 9th Congress on Trends in Medical Mycology (TIMM-9) Highlighting Scientific and Clinical Evidence of Ibrexafungerp's Activity Against Resistant Fungal Pathogens, Including Candida auris
Sep 09, 2019
FDA Grants Fast Track Status to Amplyx Pharmaceuticals for IV and Oral Formulations of Fosmanogepix (APX001) for Seven Different Indications
Mar 14, 2019
SCYNEXIS Reports Full Year 2018 Financial Results and Provides Company Update
Feb 28, 2019
SCYNEXIS to Present Pre-clinical Data Supporting Prophylactic Use of Ibrexafungerp at Superbugs and Superdrugs 2019
Jan 30, 2019
SCYNEXIS Announces Positive Interim Results from Phase 3 Open-Label FURI Study, Showing Oral Ibrexafungerp's Ability to Treat Refractory Fungal Infections and to Provide an Alternative to Long-Term IV Therapies
Nov 13, 2018
Amplyx Doses First Patient in Phase 2 Trial of APX001 in Patients with Candida Infection
Oct 15, 2018
SCYNEXIS, Inc. Announces First Patient Dosed in Phase 3 Open-label Study Evaluating Oral Ibrexafungerp in Candida auris Infections (CARES)
Jul 18, 2018
The World Health Organization Recognizes New Antifungal Class by Granting "ibrexafungerp" to SCYNEXIS as the International Non-Proprietary Name for SCY-078
Jun 27, 2018
SCYNEXIS Announces the Presentation of SCY-078 Data at the Teratology Society 58th Annual Meeting
Jun 11, 2018
SCYNEXIS Presents SCY-078 Data at ASM Microbe 2018
May 24, 2018
SCYNEXIS to Present SCY-078 Data at ASM Microbe 2018